Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 61NIH 14NETWORK 9INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 282Carboplatin 217Cisplatin 147Gemcitabine 146Paclitaxel 142Bevacizumab 116Pemetrexed 114Docetaxel 101Oxaliplatin 79durvalumab 78Dexamethasone 77Fluorouracil 76atezolizumab 75Nivolumab 75Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 70Capecitabine 64Cetuximab 63Injections 62Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 50venetoclax 44Prednisone 43Irinotecan 42Letrozole 40enzalutamide 39tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Radiotherapy, Intensity-Modulated × 90 days × Clear all
NCT07219212 2026-06-05

LUMIRAY

Johnson & Johnson Enterprise Innovation Inc.

Phase 1 Recruiting
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡